Dare Bioscience, Inc.

DARE Nasdaq SEC CIK 1401914
Follow Dare Bioscience Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $47.6K +2005.6% vs same quarter last year
Net income −$3.2M +11.4% vs same quarter last year
EPS, diluted −$0.18 +35.7% vs same quarter last year
Operating cash flow −$6.8M −1084.9% vs same quarter last year
Revenue by quarter
$25.4K
$2.3K
$1M
$152.5K
$187.5K
$47.6K
Q1 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$1M−$13.4M
FY24$9.8K−$4.1M
FY23$2.8M−$30.2M
FY22$10M−$30.9M
FY21$0−$38.7M
FY20-−$27.4M
FY19-−$14.3M
FY18-−$16.7M
FY17--
FY16$766K−$672.7K
FY15-−$39.6M
FY14$80K−$23.3M
FY13$6K−$17.1M
FY12$625K−$22.1M
FY11--
MarginsShare of revenue
  • Operating margin
  • Net margin
−300000%−200000%−100000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−1315.5%−1300.7%
FY24−239692.2%−41394.1%
FY23−1101.9%−1074.1%
FY22−313.9%−309.5%
FY21--
FY20--
FY19--
FY18--
FY17--
FY16−82.3%−87.8%
FY15--
FY14-−29177.5%
FY13-−285716.7%
FY12-−3536.2%
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$10.3M
FY24$4.9M
FY23−$39.5M
FY22−$18.2M
FY21−$28.8M
FY20−$25.3M
FY19−$13.3M
FY18−$10.3M
FY17−$2.5M
FY16−$907.3K
FY15−$32.2M
FY14−$19.3M
FY13−$16.6M
FY12−$21.2M
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Dare Bioscience
  • Healthcare median
−300000%−200000%−100000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearDare BioscienceHealthcare median
FY25−1300.7%−30.6%
FY24−41394.1%−47%
FY23−1074.1%−58%
FY22−309.5%−80.4%
FY21-−71.9%
FY20-−62.2%
FY19-−46.3%
FY18-−49.6%
FY17-−45.9%
FY16−87.8%−36%
FY15-−38.4%
FY14−29177.5%−35.5%
FY13−285716.7%−37.1%
FY12−3536.2%−29.1%
FY11-−27.9%